Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Molecular Templates Inc MTEMQ

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (GREY:MTEMQ)

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

GlobeNewswire April 23, 2025

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

GlobeNewswire December 19, 2024

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

GlobeNewswire December 2, 2024

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire August 14, 2024

Molecular Templates, Inc. Provides Interim Update

GlobeNewswire June 3, 2024

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire May 15, 2024

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

GlobeNewswire April 9, 2024

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

GlobeNewswire March 29, 2024

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

GlobeNewswire March 28, 2024

Bullboard Posts (GREY:MTEMQ)

Molecular Templates (MTEM): Pioneering Innovative Engineered

Interesting play in the biotech space. MTEM's ETB platform looks promising with some solid early data. MT-6402 showing partial...
MikeTester - January 23, 2025

Molecular Templates, Inc. (MTEM): A Promising Biotech Naviga

http://beyondspx.com/2024/08/01/molecular-templates-inc-mtem-a-promising-biotech-navigating-the-challenges-of-innovative-immunotoxin...
MikeTester - August 1, 2024

4 BIOTECH STOCKS THAT WARRANT YOUR ATTENTION!

$MTEM $STRO $SNDX $KRYS Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these...
AviseAnalytics - October 5, 2021

Alert ticker Asti otc gains of 11% crossed 10ma trendline

ATTENTION ATTENTION $ASTI SALES ARE UP, the OFFICIAL SHORT SQUEEZE WILL CAUSE the SHORTS TO COVER AT HIGHER PRICES.  Currently...
kseanng - September 23, 2016

Finally

I"ve been waiting so long for upswing. Nice.
JawDrop - July 13, 2010

people are in

Does people are in this stock ??? I'm full I will buy more if it past 4$ I will buy 10 000 more shares
bonoway - January 18, 2007